New Production Plant in Slovenia is Constructed to Produce Epoetin Alfa

According to this article in in-Pharma Technologists Lek has opened up a manufacturing facility in Slovenia to produce epoetin alfa drug for biosimilars which is marketed by its parent company Sandoz. The addition of the new facility will help boost production of the drug which was originally marketed by Johnson & Johnson.

The huge investment have been used to uild a 430m² production plant that will become a global supply point for Sandoz modified proteins. Zvonko Bogdanovski, a member of the Lek board of management mentions “Our endeavours in biopharmaceuticals will have an important impact on health systems going forward.”

Share this article with your social network, just click below to share now!

Share |

Biosimilars proving to match regular drugs

At Pharmacy Europe, they look at the results of the biosimilar epoetin zeta, which was tested against epoetin alfa.

The results were as follows:
A study was performed to assess these different product formulations by using and comparing an array of analytical techniques for product characterisation, including reversed-phase high-performance liquid chromatography (RP-HPLC). The RP-HPLC analysis demonstrated that the presence of polysorbate 80 in the formulation of epoetin alfa caused considerable peak interference, with chromatograms of epoetin alfa samples showing greater fragmentation of the main epoetin peak compared with epoetin zeta. The epoetin zeta formulation offers some advantages over epoetin alfa in terms of the drug product analysis performed according to the methods used in this study.

This could be further proof that biosimilars are a viable alternative for patients. Read the full article here.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |